Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1Dermatologic 1CNS 1

Conditions

Pituitary Neoplasms 7Neuroendocrine Tumors 6Carcinoid Tumor 5Acromegaly 5Gastro-enteropancreatic neuroendocrine tumor 3Pituitary ACTH Hypersecretion 2Growth Disorders 2Gigantism 2Serotonin Syndrome 1Prostatic Neoplasms 1Prolactin-Producing Pituitary Tumor 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Nelson Syndrome 1Melanoma 1Lymphoma, Follicular 1Liver Neoplasms 1Insulinoma 1Hypoglycemia 1Hyperinsulinism 1Dumping Syndrome 1Congenital Hyperinsulinism 1Carcinoma, Neuroendocrine 1Carcinoma 1Adrenocortical Hyperfunction 1Adenoma, Islet Cell 1ACTH Syndrome, Ectopic 1

Interventions

Everolimus 6Sunitinib 4Octreotide 4Leucovorin 4dabrafenib 3Fluorouracil 33-Iodobenzylguanidine 3trametinib 2selpercatinib 2lutetium Lu 177 dotatate 2avelumab 2alectinib 2PM 01183 2Oxaliplatin 2Irinotecan 2Fulvestrant 2Drug Therapy 2Doxorubicin 2Cisplatin 2trifluridine tipiracil drug combination 1tipifarnib 1telotristat ethyl 1surufatinib 1somapacitan 1ribociclib 1repotrectinib 1pralsetinib 1pentetreotide 1pegfilgrastim 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × pasireotide × Endocrine × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡